States sue Abbott for 'blocking' generics

And the battle over generics rages on. Eighteen states have filed an antitrust suit against Abbott Laboratories, saying the drugmaker blocked generic competition for its blockbuster cholesterol med TriCor. According to the suit, which also names the French pharma Fournier, the companies continuously tweaked the TriCor formula to keep generic versions off the market. It also claims that they deceived the U.S. Patent Office with misleading data.

Abbott says it hasn't kept TriCor copycats off the market; in fact, there are eight competing products, according to a company spokeswoman. A Fournier rep says it didn't do anything wrong and intends to "vigorously defend itself" against the charges.

- see the release from Florida AG Bill McCollum
- read the complaint from the Florida AG's website
- see the International Herald Tribune story
- check out more details in the Chicago Tribune

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.